TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).

A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 10 October 2026).

A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.